BIIB Biogen

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

Company profile

Michel Vounatsos
Fiscal year end
Former names
IRS number

BIIB stock data



3 Feb 21
18 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Biogen earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.33B 1.33B 1.33B 1.33B 1.33B 1.33B
Cash burn (monthly) 297.87M 131.88M 110.2M (positive/no burn) 122.37M (positive/no burn)
Cash used (since last report) 1.07B 475.57M 397.4M n/a 441.28M n/a
Cash remaining 257.03M 855.63M 933.8M n/a 889.92M n/a
Runway (months of cash) 0.9 6.5 8.5 n/a 7.3 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
18 Feb 21 Alexander Susan H RSU Common Stock Grant Aquire A No No 0 10,870 0 10,870
18 Feb 21 Alphonse Galdes RSU Common Stock Grant Aquire A No No 0 10,870 0 10,870
18 Feb 21 Ginger Gregory RSU Common Stock Grant Aquire A No No 0 10,150 0 10,150
18 Feb 21 Chirfi Guindo RSU Common Stock Grant Aquire A No No 0 14,500 0 14,500
18 Feb 21 Kramer Robin RSU Common Stock Grant Aquire A No No 0 2,900 0 2,900

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

84.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1022 1008 +1.4%
Opened positions 167 100 +67.0%
Closed positions 153 99 +54.5%
Increased positions 272 299 -9.0%
Reduced positions 414 408 +1.5%
13F shares
Current Prev Q Change
Total value 31.57B 37.13B -15.0%
Total shares 128.45M 128.68M -0.2%
Total puts 5.83M 4.6M +26.9%
Total calls 5.76M 3.75M +53.7%
Total put/call ratio 1.0 1.2 -17.5%
Largest owners
Shares Value Change
Primecap Management 15.82M $3.87B +0.8%
BLK Blackrock 13.42M $3.29B -7.2%
Vanguard 11.9M $2.91B -3.7%
STT State Street 6.99M $1.71B -7.1%
Wellington Management 5.78M $1.42B +19.0%
Clearbridge Advisors 3.6M $881.17M -10.4%
Renaissance Technologies 3.04M $743.83M -20.4%
JPM JPMorgan Chase & Co. 2.91M $713.04M +40.4%
Geode Capital Management 2.76M $674.21M -4.5%
NTRS Northern Trust 2.2M $538.93M -7.6%
Largest transactions
Shares Bought/sold Change
Norges Bank 1.9M +1.9M NEW
Aqr Capital Management 1.02M -1.2M -54.1%
BLK Blackrock 13.42M -1.04M -7.2%
Wellington Management 5.78M +924.78K +19.0%
FMR 1.98M +897.04K +82.7%
JPM JPMorgan Chase & Co. 2.91M +838.3K +40.4%
Renaissance Technologies 3.04M -779.2K -20.4%
BLVGF Bellevue 564K +555.4K +6458.1%
STT State Street 6.99M -531.68K -7.1%
Vanguard 11.9M -451.56K -3.7%

Financial report summary

  • We are substantially dependent on revenues from our products.
  • Our long-term success depends upon the successful development of new products and additional indications for our existing products.
  • If we fail to compete effectively, our business and market position would suffer.
  • We depend on relationships with collaborators, joint venture partners and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.
  • Our results of operations may be adversely affected by current and potential future healthcare reforms.
  • Our success in commercializing biosimilars developed by Samsung Bioepis is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If Samsung Bioepis is unsuccessful in such activities, we may not realize the anticipated benefits of our investment in Samsung Bioepis.
  • Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.
  • Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.
  • Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.
  • The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.
  • The increasing use of social media platforms presents new risks and challenges.
  • If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed.
  • The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.
  • A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.
  • Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.
  • If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.
  • Our sales and operations are subject to the risks of doing business internationally.
  • We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.
  • Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.
  • Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.
  • Our operating results are subject to significant fluctuations.
  • Our investments in properties may not be fully realized.
  • Our investment portfolio is subject to market, interest and credit risk that may reduce its value.
  • There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.
  • We may not be able to access the capital and credit markets on terms that are favorable to us.
  • Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business.
  • Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.
Content analysis
H.S. freshman Avg
New words: Abeta, AccessAbility, ACR, adjunctive, aflibercept, African, AHEAD, Aid, alpha, amortizable, andMovement, annul, Annulment, antigen, app, Armata, array, arthritisAxial, arthritisCrohn, arthritisJuvenile, arthritisPsoriasisPaediatric, arthritisPsoriatic, arthritisTwo, attached, ATV, Bachelor, back, begun, BioDiversity, Black, bolster, border, caliber, CCPA, child, childcare, chlorambucil, climate, CLLFollicular, coach, colitisAnkylosing, colitisPaediatric, colitisUveitisPaediatric, commentary, compassionate, compliant, condensed, contractor, cope, DAC, deepen, deeply, degeneration, Denali, dendritic, diabetic, diseasePaediatric, diseaseUlcerative, DISH, dispensed, dispensing, divergent, DME, EchoStar, elevated, email, EMBARK, empower, empowering, endothelial, English, entirety, equitable, equitably, essential, estoppel, ethnic, expressed, expression, feel, female, fidelity, finger, flat, fossil, FranceGermany, FranceGermanyItaly, Georgetown, globe, great, guide, hacking, Hammersmith, headache, Headspace, heard, HFMSE, highest, home, humanitarian, IGNITE, IM, Immersing, immunogenicity, implication, incumbent, indirectly, inspired, Intelsat, intermediate, intolerance, invaluable, IQVIA, isolation, job, knowledge, lab, Lancet, Latinx, length, LGBTQ, lowest, lymphomaCLL, lymphomaCLLRheumatoid, lymphomaIn, MAA, macular, magnetic, mcdonnell, MCG, MDD, meditation, mentoring, mobile, modestly, morale, Mosaic, NaN, nausea, neovascular, nm, nonrecurring, Notably, occlusion, ourIMPACT, pandemic, paramount, Partnership, PDUFA, Peripheral, philosophy, plasmacytoid, Portuguese, postpartum, PPD, proactive, problem, Prolonged, psoriasisPaediatric, pulse, racial, racism, ranibizumab, ReachOUT, recharging, redosing, refraining, refreshed, release, reluctance, remyelination, renowned, resonance, retinopathy, Retreat, reward, rigor, route, sage, satellite, sc, shape, shelter, Shilpa, similarly, slowdown, solution, Spanish, spondylitisPsoriatic, spondyloarthritisPlaque, spondyloarthritisPsoriatic, spread, statutorily, strain, suppurativaAdolescent, suppurativaCrohn, supraneuclear, survey, Taiwan, teen, toferson, transport, travel, tremor, trust, ulcerative, unacceptable, underrepresented, underway, unprecedented, User, vascular, vast, Vehicle, vein, virtual, volunteering, Waltham, wet, workplace, zinc, zuranolone
Removed: AAV, abroad, AD, afforded, ALPROLIX, AmerisourceBergen, Antihemophilic, Article, Aurobindo, Bayer, Beacon, BENEPALITM, BETASERON, Carlyle, cerebral, complaint, confirmed, Congressional, continuation, cooperating, coupon, curtail, decided, declaratory, decreased, depart, dismissed, disproportionately, Duke, ELOCTA, ELOCTATE, EMD, enabling, evolution, exit, EXTAVIA, FAMPYRATM, fatal, Fc, finalization, FLIXABITM, floating, formally, founder, fulminant, FUMADERMTM, Fusion, genetic, glatiramer, Glenmark, glibencamide, hour, immunomodulation, IMRALDITM, interference, interpreting, invalidity, Italia, Jersey, Johnson, joined, learned, LIBOR, liver, lumbosacral, macroeconomic, marketer, McKenzie, McKesson, Milan, Monomoy, mortality, Neurocrine, notified, observational, outflow, partnering, Paul, Pennsylvania, placebo, PLSR, prove, radiculopathy, rapidly, REBIF, referendum, Remedy, repayment, replacement, restructuring, ruling, Sawai, score, SEC, seller, separately, Serono, Shipla, staffing, stake, succeeding, swelling, tenure, tool, transitioning, Treasurer, unknown, unrecorded, Vermont, voluntarily, wage, weak, Zug